Robert Goulart to Papillomavirus Infections
This is a "connection" page, showing publications Robert Goulart has written about Papillomavirus Infections.
Connection Strength
1.292
-
Pantanowitz L, Hornish M, Cao QJ, Goulart RA. HPV data can be used as a cytopathology laboratory quality indicator. Diagn Cytopathol. 2010 Feb; 38(2):159-60.
Score: 0.303
-
Nayar R, Chhieng DC, Crothers B, Darragh TM, Davey DD, Eisenhut C, Goulart R, Huang EC, Tabbara SO. Moving forward-the 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors and beyond: implications and suggestions for laboratories. J Am Soc Cytopathol. 2020 Jul - Aug; 9(4):291-303.
Score: 0.155
-
Huh WK, Ault KA, Chelmow D, Davey DD, Goulart RA, Garcia FAR, Kinney WK, Massad LS, Mayeaux EJ, Saslow D, Schiffman M, Wentzensen N, Lawson HW, Einstein MH. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Obstet Gynecol. 2015 Feb; 125(2):330-337.
Score: 0.107
-
Huh WK, Ault KA, Chelmow D, Davey DD, Goulart RA, Garcia FA, Kinney WK, Massad LS, Mayeaux EJ, Saslow D, Schiffman M, Wentzensen N, Lawson HW, Einstein MH. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol Oncol. 2015 Feb; 136(2):178-82.
Score: 0.107
-
Nayar R, Goulart RA, Tiscornia-Wasserman PG, Davey DD. Primary human papillomavirus screening for cervical cancer in the United States-US Food and Drug Administration approval, clinical trials, and where we are today. Cancer Cytopathol. 2014 Oct; 122(10):720-9.
Score: 0.104
-
Davey DD, Goulart R, Nayar R. Update on HPV test utilization. Am J Clin Pathol. 2014 May; 141(5):759.
Score: 0.102
-
Davis Davey D, Davey DD, Goulart R, Nayar R. 2013 statement on human papillomavirus test utilization [corrected]. Diagn Cytopathol. 2014 May; 42(5):449-52.
Score: 0.101
-
Davey DD, Goulart R, Nayar R. 2013 statement on human papillomavirus DNA test utilization. Am J Clin Pathol. 2014 Apr; 141(4):459-61.
Score: 0.101
-
Davis Davey D, Goulart R, Nayar R. 2013 statement on human papillomavirus [corrected] test utilization. Acta Cytol. 2014; 58(2):113-6.
Score: 0.100
-
Davis Davey D, Goulart R, Nayar R. 2013 statement on human papillomavirus [corrected] test utilization. Cancer Cytopathol. 2014 Feb; 122(2):83-6.
Score: 0.099
-
Pantanowitz L, Florence RR, Goulart RA, Otis CN. Trichomonas vaginalis P16 Immunoreactivity in cervicovaginal Pap tests: a diagnostic pitfall. Diagn Cytopathol. 2005 Sep; 33(3):210-3.
Score: 0.014